Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience

Despite the well-defined role of autologous haematopoietic stem cell transplantation (autoHCT) in the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL), relapse remains the main cause of transplant failure. We retrospectively evaluated long-term outcome and prognostic factors a...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2013, Vol.30 (3), p.611, Article 611
Main Authors: Czyz, Anna, Lojko-Dankowska, Anna, Dytfeld, Dominik, Nowicki, Adam, Gil, Lidia, Matuszak, Magdalena, Kozlowska-Skrzypczak, Maria, Kazmierczak, Maciej, Bembnista, Ewa, Komarnicki, Mieczysław
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carmustine - therapeutic use
Cytarabine - therapeutic use
Disease-Free Survival
Etoposide - therapeutic use
Female
Hematology
Hematopoietic Stem Cell Transplantation
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Hodgkin Disease - pathology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Melphalan - therapeutic use
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Oncology
Original Paper
Pathology
Prognosis
Retrospective Studies
Risk Factors
Transplantation, Autologous
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the well-defined role of autologous haematopoietic stem cell transplantation (autoHCT) in the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL), relapse remains the main cause of transplant failure. We retrospectively evaluated long-term outcome and prognostic factors affecting survival of 132 patients with refractory ( n  = 89) or relapsed HL ( n  = 43) treated with autoHCT following modified BEAM. With a median follow-up of 68 months, the 10-year overall survival (OS) and progression-free survival (PFS) were 76 and 66 %, respectively. The 10-year cumulative incidence of second malignancies was 7 %. In multivariate analysis, age ≥45 years, more than one salvage regimens and disease status at transplant worse than CR were factors predictive for poor OS. In relapsed HL, age at transplant, response duration (
ISSN:1357-0560
1559-131X
DOI:10.1007/s12032-013-0611-y